NASDAQ:CDXS
Codexis Stock News
$3.92
+0.580 (+17.37%)
At Close: May 03, 2024
Codexis' (CDXS) CEO John Nicols on Q3 2021 Results - Earnings Call Transcript
09:00pm, Thursday, 04'th Nov 2021
Codexis' (CDXS) CEO John Nicols on Q3 2021 Results - Earnings Call Transcript
Codexis to Report Third Quarter 2021 Financial Results on November 4
04:05pm, Thursday, 21'st Oct 2021
REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report
Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?
07:35am, Wednesday, 20'th Oct 2021
Codexis is leveraging its core technology to create more effective life science tools.
REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboratio
Codexis (CDXS) Surges 12.4%: Is This an Indication of Further Gains?
10:16am, Monday, 04'th Oct 2021
Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin
07:43am, Friday, 10'th Sep 2021
Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin. Sitagliptin is an act
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
04:05pm, Thursday, 09'th Sep 2021
REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and exten
Codexis to Participate in Upcoming Virtual Healthcare Conferences
04:05pm, Tuesday, 07'th Sep 2021
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management w
After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright
10:53am, Tuesday, 10'th Aug 2021
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript
03:18pm, Saturday, 07'th Aug 2021
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
09:17pm, Thursday, 05'th Aug 2021
Codexis (CDXS) delivered earnings and revenue surprises of 58.82% and 41.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, I
ARK Investment Leans Into Biotech and Telecom Holdings
03:39pm, Monday, 12'th Jul 2021
Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.
Codexis Earns Milestone Payment from GlaxoSmithKline
04:05pm, Wednesday, 07'th Jul 2021
REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant
Strength Seen in Codexis (CDXS): Can Its 12.6% Jump Turn into More Strength?
01:31am, Monday, 21'st Jun 2021
Codexis (CDXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
